M 230

Drug Profile

M 230

Alternative Names: CSL 730; CSL 730 rFc Multimer; M230; Recombinant trivalent human IgG1 Fc multimer; SIF3

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Momenta Pharmaceuticals
  • Class Antirheumatics; Immunoglobulins; Recombinant proteins; Skin disorder therapies
  • Mechanism of Action Fc receptor modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders
  • Preclinical Epidermolysis bullosa; Idiopathic thrombocytopenic purpura

Most Recent Events

  • 22 Jan 2018 Phase-I clinical trials in Autoimmune disorders (In volunteers) (IV) (9233950; NCT03375606)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top